The Effect of Curcumin Pill in Treatment of Non-alcoholic Fatty Liver Disease: A Clinical Trial Study

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Internal Medicine, School of Medicine AND Isfahan Bone Metabolic Disorders Research Center, Isfahan University of Medical Sciences, Isfahan Iran

2 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Gastroenterologist, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Science, Isfahan, Iran

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease across the world. Due to the high prevalence of NAFLD, some patients tend to use herbal medicines for its treatment. The aim of the present study was to evaluate the effects of curcumin pill on NAFLD.Methods: In this clinical trial study, 100 patients with NAFLD were enrolled. Then, their height, weight, and body mass index were measured, and liver function tests and liver ultrasound were performed, too. The patients were then divided into two groups of case and control, and received curcumin and placebo for eight weeks, respectively. Before and after intervention, fasting blood sugar (FBS), lipid profile levels [including total cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein (HDL)], human C-reactive protein (hCRP) level, and liver markers such as aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine transaminase (ALT) were measured and recorded again. Data were analyzed and compared between two groups using SPSS software.Findings: There was no significant difference between the two groups in terms of gender, age, clinical features, total cholesterol, triglyceride, LDL, HDL, FBS, liver function markers such as ALP, ALT, and AST, and hCRP, and fatty liver grade at the onset of the study (P > 0.050). However, the level of ALT, AST, and hCRP significantly reduced in the case group after the intervention (P < 0.001).Conclusion: According to the results of the present study, it seems that curcumin can be recommended for appropriate treatment of NAFLD.

Keywords

References

  1. Namakin K, Hosseini M, Zardast M, Mohammadifard M. Prevalence of non-alcoholic fatty liver disease (NAFLD) and its clinical characteristics in overweight and obese children in the south east of Iran, 2017. Hepat Mon 2018; 18(12): e83525.
  2. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52(1): 79-104.
  3. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 2013; 39(1): 2-13.
  4. Zabihi NA, Pirro M, Johnston TP, Sahebkar A. Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des 2017; 23(7): 969-82.
  5. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999; 39(1): 41-7.
  6. Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 2013; 113(3): 152-7.
  7. Vizzutti F, Provenzano A, Galastri S, Milani S, Delogu W, Novo E, et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest 2010; 90(1): 104-15.
  8. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992; 36(4): 273-5.
  9. Xie YL, Chu JG, Jian XM, Dong JZ, Wang LP, Li GX, et al. Curcumin attenuates lipopolysaccharide/d-galactosamine-induced acute liver injury by activating Nrf2 nuclear translocation and inhibiting NF-kB activation. Biomed Pharmacother 2017; 91: 70-7.
  10. Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 2019; 73(3): 441-9.
  11. Wei Z, Liu N, Tantai X, Xing X, Xiao C, Chen L, et al. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Hepatol Int 2019; 13(3): 302-13.
  12. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001; 131(11): 2932-5.
  13. Ayoubi A, Valizadeh R, Omidi A, Abolfazli M. Evaluation of turmeric (Curcuma longa) effects in preventing consequences of lead acetate in male rats. J Birjand Univ Med Sci 2014; 21(1): 68-76. [In Persian].
  14. Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008; 52(9): 995-1004.
  15. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int 2009; 29(10): 1457-66.
  16. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. J Cardiovasc Pharmacol 2016; 68(3): 223-9.
  17. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial. Phytother Res 2016; 30(9): 1540-8.
  18. Naik SR, Thakare VN, Patil SR. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant property. Exp Toxicol Pathol 2011; 63(5): 419-31.
  19. Li B, Wang L, Lu Q, Da W. Liver injury attenuation by curcumin in a rat NASH model: An Nrf2 activation-mediated effect? Ir J Med Sci 2016; 185(1): 93-100.
  20. Zhao NJ, Liao MJ, Wu JJ, Chu KX. Curcumin suppresses Notch1 signaling: Improvements in fatty liver and insulin resistance in rats. Mol Med Rep 2018; 17(1): 819-26.
Journal of Isfahan Medical School
Volume 37, Issue 538 - Serial Number 538
July and August 2019
Pages 943-949

Files

History

  • Receive Date: 08 September 2019
  • Revise Date: 07 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics